Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV

Chris Wynne, Paul Hamilton, Jingxin Li, Chen Mo, Jiaping Yu, Wenrong Yao, Zijing Yue, Xi Zhang, Jianhui Zhang, Kunxue Hong, Jianping Chen, Yong Liu, Fengcai Zhu
doi: https://doi.org/10.1101/2022.05.11.22274932
Chris Wynne
1New Zealand Clinical Research – Christchurch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Hamilton
2New Zealand Clinical Research – Auckland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingxin Li
3NHC Key laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chen Mo
4Jiangsu Recbio Technology Co., Ltd.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiaping Yu
4Jiangsu Recbio Technology Co., Ltd.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenrong Yao
4Jiangsu Recbio Technology Co., Ltd.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zijing Yue
4Jiangsu Recbio Technology Co., Ltd.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xi Zhang
4Jiangsu Recbio Technology Co., Ltd.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianhui Zhang
4Jiangsu Recbio Technology Co., Ltd.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kunxue Hong
4Jiangsu Recbio Technology Co., Ltd.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianping Chen
4Jiangsu Recbio Technology Co., Ltd.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yong Liu
4Jiangsu Recbio Technology Co., Ltd.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fengcai Zhu
3NHC Key laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, China
5Center for Global Health, Nanjing Medical University, Nanjing P. R. China
6School of Public Health, Nanjing Medical University, Nanjing, China
7Institute of Global Health and Emergency Pharmacy, China Pharmaceutical University, Nanjing, P. R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jszfc@vip.sina.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

Background The ReCOV is a recombinant trimeric two-component SARS-CoV-2 subunit vaccine adjuvanted with BFA03. We report the preliminary safety and immunogenicity results for the ReCOV.

Methods This first in human, randomized, double-blind, placebo-controlled phase I study, was conducted at 2 study sites in New Zealand. Subjects were stratified into two age cohorts (18-55 years and 56-80 years old) and then randomly assigned in a 4:1 ratio to receive two 0.5 mL intramuscular doses of the ReCOV vaccine (20µg or 40µg, adjuvanted with BFA03 in each) or placebo, 21 days apart. The primary endpoints were incidence of solicited local and systemic adverse events (AEs) and unsolicited AEs after each dose; incidence of serious adverse events (SAEs) up to 30 days after the second dose; changes in clinical laboratory tests from baseline up to 7 days after each dose; and changes in vital signs from baseline up to 30 days after the second dose. The key secondary endpoints for immunogenicity were neutralizing antibody titers against SARS-CoV-2, S1 receptor binding domain (RBD) and N-terminal domain (NTD) IgG titers post-vaccination. The T cell-specific immune response elicited by ReCOV were also evaluated. The trial was registered with ClinicalTrials.gov (NCT04818801).

Findings One hundred participants (50 for each age group) were randomized. The incidence of solicited local AEs in 20μg ReCOV, 40μg ReCOV, and pooled placebo group among younger adults were 60.0%, 70.0%, and 10.0%, respectively, while among older adults were 55.0%, 84.2%, and 10.0%, respectively. The incidence of solicited systemic AEs in 20μg ReCOV, 40μg ReCOV, and pooled placebo group among younger adults were 60.0%, 60.0%, and 30.0%, respectively, while among older adults were 50.0%, 52.6%, and 50.0%, respectively. All solicited AEs and unsolicited AEs were mild. No vaccination-related SAE, adverse events of special interest, and AE leading to early discontinuation were reported.

ReCOV elicited SARS-CoV-2 neutralizing antibody after the first vaccination, which were increased further after the second vaccination irrespective of dose and age groups. The neutralizing antibody against wild-type SARS-CoV-2 peaked at 14 days post the second vaccination in both 20µg and 40µg ReCOV groups, with GMT of 1643.17 IU/mL and 1289.21 IU/mL among younger adults, and 1122.32 IU/mL and 680.31 IU/mL among older adults, respectively. Similarly, both anti-RBD and anti-NTD specific IgG were elicited after the first vaccination, and peaked at 14 days after the second vaccination. T helper 1 biased cellular responses were observed after ReCOV vaccinations.

Interpretation Both 20 and 40µg ReCOV showed good safety profiles and elicited strong immune responses in the younger and the older adults. The results of this study support the accelerated development of ReCOV.

Funding Jiangsu Recbio Technology Co., Ltd.

Competing Interest Statement

Chen Mo, Xi Zhang, Jiaping Yu, Wenrong Yao, Zijing Yue, Kunxue Hong, Jianping Chen, Jianhui Zhang, Yong Liu are employees of Jiangsu Recbio Technology Co., Ltd. All the other authors declare no competing interests.

Clinical Trial

NCT04818801

Funding Statement

This work was funded by Jiangsu Recbio Technology Co., Ltd.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Northern B Health and Disability Ethics Committee gave ethical approval for this work. Ethics ref: 21/NTB/108.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted May 14, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV
Chris Wynne, Paul Hamilton, Jingxin Li, Chen Mo, Jiaping Yu, Wenrong Yao, Zijing Yue, Xi Zhang, Jianhui Zhang, Kunxue Hong, Jianping Chen, Yong Liu, Fengcai Zhu
medRxiv 2022.05.11.22274932; doi: https://doi.org/10.1101/2022.05.11.22274932
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV
Chris Wynne, Paul Hamilton, Jingxin Li, Chen Mo, Jiaping Yu, Wenrong Yao, Zijing Yue, Xi Zhang, Jianhui Zhang, Kunxue Hong, Jianping Chen, Yong Liu, Fengcai Zhu
medRxiv 2022.05.11.22274932; doi: https://doi.org/10.1101/2022.05.11.22274932

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Subject Areas
All Articles
  • Addiction Medicine (164)
  • Allergy and Immunology (416)
  • Anesthesia (92)
  • Cardiovascular Medicine (867)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (397)
  • Epidemiology (8589)
  • Forensic Medicine (4)
  • Gastroenterology (390)
  • Genetic and Genomic Medicine (1772)
  • Geriatric Medicine (169)
  • Health Economics (375)
  • Health Informatics (1252)
  • Health Policy (625)
  • Health Systems and Quality Improvement (472)
  • Hematology (197)
  • HIV/AIDS (380)
  • Infectious Diseases (except HIV/AIDS) (10344)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (193)
  • Medical Ethics (51)
  • Nephrology (214)
  • Neurology (1692)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (330)
  • Occupational and Environmental Health (451)
  • Oncology (933)
  • Ophthalmology (265)
  • Orthopedics (104)
  • Otolaryngology (172)
  • Pain Medicine (115)
  • Palliative Medicine (40)
  • Pathology (255)
  • Pediatrics (539)
  • Pharmacology and Therapeutics (257)
  • Primary Care Research (210)
  • Psychiatry and Clinical Psychology (1785)
  • Public and Global Health (3871)
  • Radiology and Imaging (627)
  • Rehabilitation Medicine and Physical Therapy (322)
  • Respiratory Medicine (525)
  • Rheumatology (208)
  • Sexual and Reproductive Health (170)
  • Sports Medicine (158)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)